Home/Filings/4/0001562180-22-001078
4//SEC Filing

Meyers Michael L. 4

Accession 0001562180-22-001078

CIK 0001395937other

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 5:31 PM ET

Size

7.2 KB

Accession

0001562180-22-001078

Insider Transaction Report

Form 4
Period: 2022-02-02
Meyers Michael L.
SVP, Chief Development Officer
Transactions
  • Other

    Common Stock

    2022-01-31$12.39/sh+1,714$21,23623,280 total
  • Award

    Stock Options (Right to buy)

    2022-02-02$15.79/sh+17,350$273,95717,350 total
    Exercise: $15.79Exp: 2032-02-02Common Stock (17,350 underlying)
Footnotes (2)
  • [F1]The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F2]1/23rd of the shares subject to the option shall vest monthly over a two-year period.

Issuer

Syndax Pharmaceuticals Inc

CIK 0001395937

Entity typeother

Related Parties

1
  • filerCIK 0001664204

Filing Metadata

Form type
4
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 5:31 PM ET
Size
7.2 KB